Want to see CTKB full AI Analyst Report?
CTKB Stock Chart & Stats
$4.57
-$0.05(-1.12%)
At close: 4:00 PM EDT
$4.57
-$0.05(-1.12%)
Day’s Range― - ―
52-Week Range$3.28 - $6.18
Previous Close$4.44
Volume521.40K
Average Volume (3M)777.24K
Market Cap
$610.92M
Enterprise Value$346.69
Total Cash (Recent Filing)$262.00M
Total Debt (Recent Filing)$26.46M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding129,983,250
10 Day Avg. Volume655,014
30 Day Avg. Volume777,237
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside31.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$208.83M
Bulls Say, Bears Say
Bulls Say
Growing Installed Base And Recurring RevenueThe expanding installed base creates a durable foundation for reagent, consumable, software and service demand. Recurring revenue growth increases customer lifetime value and should make future revenue less dependent on laboratory capital-equipment cycles.
Product Innovation And Ecosystem ExpansionNew high-parameter and automated instruments broaden Cytek’s addressable workflows, while cloud adoption strengthens customer engagement. Together, the product and software ecosystem can support differentiation and pull-through demand for recurring offerings.
Conservative Balance SheetVery low leverage and substantial liquidity provide flexibility to fund product development, commercialization and potential legal costs without immediate dependence on debt markets. This gives Cytek resilience while it works to restore profitability and cash generation.
Bears Say
Persistent Losses And Negative Cash FlowThe reversal from positive prior-year cash generation to operating and free-cash-flow burn indicates weak operating leverage and raises funding risk if sustained. Deep losses also limit the company’s ability to self-finance expansion despite its cash reserves.
Regional And Clinical Market LimitationsGeographic budget pressure and uneven APAC performance make growth less predictable, while limited U.S. clinical approval constrains access to an important market. These structural barriers may delay broader adoption and increase dependence on research customers.
Patent Litigation And Higher Operating CostsThe damages award creates legal and financial exposure even though Cytek said no product changes are required and plans to appeal. Elevated litigation-related spending compounds already weak operating leverage and could divert resources from growth initiatives.
CTKB FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was $3.28 and its highest was $6.18 in the past 12 months.
What is Cytek Biosciences’s market cap?
Cytek Biosciences’s market cap is $610.92M.
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Aug 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.003.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is -0.07.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 129,983,250 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went down -0.478%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Currently, no hedge funds are holding shares in CTKB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytek Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (31.29% Upside)
$6.00 (31.29% Upside)
Blogger Sentiment
Bullish
CTKB Sentiment 75%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 462.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytek Biosciences
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
CTKB Company Deck
CTKB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.View all CTKB earnings summariesCTKB Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$6.00
▲(31.29% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
8.47% Insiders
13.06% Mutual Funds
12.38% Other Institutional Investors
54.57% Public Companies and
Individual Investors











